We then performed cell viability assays using 24 OCa cell lines representing four different subtypes of OCa including 12 established, six primary tumor derived and six ascites-derived OCa cell lines to see if addition of LIFR inhibitor EC359 blocks LIF/LIFR autocrine signaling (Fig. 2a). The gene discussed is LIF; the disease is neoplasm.